TL1A
-
A long-acting anti-TL1A mAb with best-in-class potential
If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)